Randomized Controlled Trial of Healthy Divas : A Gender-Affirming, Peer-Delivered Intervention to Improve HIV Care Engagement Among Transgender Women Living With HIV
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND: Transgender women are disproportionately affected by HIV and are less likely to be optimally engaged in care than other groups because of psychosocial challenges. With community collaboration, we developed Healthy Divas, an individual-level intervention to increase healthcare empowerment and gender affirmation to improve engagement in HIV care. Healthy Divas comprises 6 peer-led individual sessions and one group workshop facilitated by a healthcare provider with expertise in HIV care and transgender health.
SETTING/METHODS: To test the intervention's efficacy, we conducted a randomized controlled clinical trial in San Francisco and Los Angeles among transgender women living with HIV; control was no intervention. Transgender field staff conducted recruitment. Assessments occurred at baseline and 3, 6, 9, and 12 months postrandomization. The primary outcome was engagement in HIV care, defined as the sum of (1) self-reported HIV care provider visit, past 6 months, (2) knowledge of most recent CD4 count, (3) self-reported antiretroviral therapy adherence ≥90%, and (4) self-reported antiretroviral therapy adherence ≥80%.
RESULTS: We enrolled 278 participants; almost half (46%) were African American/Black and one-third (33%) were Hispanic/Latina. At 6 months, participants in the intervention arm had over twice the odds of being in a higher HIV care engagement category than those in the control arm (aOR = 2.17; 95% CI: 1.06 to 4.45; P = 0.04); there were no significant study arm differences in the outcome at the other time points.
CONCLUSIONS: This trial demonstrates the short-term efficacy of an urgently needed behavioral intervention to improve engagement in HIV care among transgender women living with HIV; ongoing intervention may be needed to maintain positive impact over time.
TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03081559.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Journal of acquired immune deficiency syndromes (1999) - 90(2022), 5 vom: 15. Aug., Seite 508-516 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sevelius, Jae M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Retroviral Agents |
|---|
| Anmerkungen: |
Date Completed 13.07.2022 Date Revised 27.09.2023 published: Print-Electronic ClinicalTrials.gov: NCT03081559 Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAI.0000000000003014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340316292 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340316292 | ||
| 003 | DE-627 | ||
| 005 | 20231226004856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAI.0000000000003014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340316292 | ||
| 035 | |a (NLM)35502891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sevelius, Jae M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Randomized Controlled Trial of Healthy Divas |b A Gender-Affirming, Peer-Delivered Intervention to Improve HIV Care Engagement Among Transgender Women Living With HIV |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.07.2022 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03081559 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND: Transgender women are disproportionately affected by HIV and are less likely to be optimally engaged in care than other groups because of psychosocial challenges. With community collaboration, we developed Healthy Divas, an individual-level intervention to increase healthcare empowerment and gender affirmation to improve engagement in HIV care. Healthy Divas comprises 6 peer-led individual sessions and one group workshop facilitated by a healthcare provider with expertise in HIV care and transgender health | ||
| 520 | |a SETTING/METHODS: To test the intervention's efficacy, we conducted a randomized controlled clinical trial in San Francisco and Los Angeles among transgender women living with HIV; control was no intervention. Transgender field staff conducted recruitment. Assessments occurred at baseline and 3, 6, 9, and 12 months postrandomization. The primary outcome was engagement in HIV care, defined as the sum of (1) self-reported HIV care provider visit, past 6 months, (2) knowledge of most recent CD4 count, (3) self-reported antiretroviral therapy adherence ≥90%, and (4) self-reported antiretroviral therapy adherence ≥80% | ||
| 520 | |a RESULTS: We enrolled 278 participants; almost half (46%) were African American/Black and one-third (33%) were Hispanic/Latina. At 6 months, participants in the intervention arm had over twice the odds of being in a higher HIV care engagement category than those in the control arm (aOR = 2.17; 95% CI: 1.06 to 4.45; P = 0.04); there were no significant study arm differences in the outcome at the other time points | ||
| 520 | |a CONCLUSIONS: This trial demonstrates the short-term efficacy of an urgently needed behavioral intervention to improve engagement in HIV care among transgender women living with HIV; ongoing intervention may be needed to maintain positive impact over time | ||
| 520 | |a TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03081559 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Dilworth, Samantha E |e verfasserin |4 aut | |
| 700 | 1 | |a Reback, Cathy J |e verfasserin |4 aut | |
| 700 | 1 | |a Chakravarty, Deepalika |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Danielle |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Mallory O |e verfasserin |4 aut | |
| 700 | 1 | |a McCree, Breonna |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Mata, Raymond P |e verfasserin |4 aut | |
| 700 | 1 | |a Neilands, Torsten B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of acquired immune deficiency syndromes (1999) |d 1999 |g 90(2022), 5 vom: 15. Aug., Seite 508-516 |w (DE-627)NLM101679912 |x 1944-7884 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2022 |g number:5 |g day:15 |g month:08 |g pages:508-516 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAI.0000000000003014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2022 |e 5 |b 15 |c 08 |h 508-516 | ||